Kaching. Look which company is set to meet an inmet need in stem cell production. It’s happening.
Dr. Robert Hariri, Founder, Chairman and CEO of Celularity, Inc. commented: “The value in the Cymerus platform is its unique ability to produce therapeutic grade mesenchymal stem cells at scale. Our stem cell therapies would immensely benefit from mass production and it is for this reason we have chosen to enter into a MoU with Cynata. A cooperation between our two companies has the potential to lead to any number of new commercial opportunities and I look forward to working alongside Cynata to explore the opportunities available to us.”
myeloma, Crohn’s disease, diabetic peripheral neuropathy and diabetic foot ulcer
CONTACTS:
Ends
Kaching. Look which company is set to meet an inmet need in stem...
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $52.99M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 29.5¢ | 27.5¢ | $29.94K | 106.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 27.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 10159 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| CYP (ASX) Chart |